Adult urologyPrevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer
Section snippets
Study Group
This was a cross-sectional study that included 390 patients with PCa who were free of bone metastases. PCa was staged at diagnosis as localized in 185 patients (47.4%), locally advanced in 161 (41.3%), and metastatic lymph node disease in 44 (11.3%). The primary treatment of PCa was radical prostatectomy in 157 patients (40.3%) and ADT in 233 (59.7%). Other characteristics of the study population are summarized in Table 1. Patients treated with radiotherapy, patients with positive bone
Results
The prevalence of osteoporosis increased progressively during ADT, reaching almost 50% after 4 years of ADT and more than 80% after 10 years. In contrast, it affected 35.4% of hormone-naive patients with PCa. Conversely, a normal BMD was detected in 19.4% of hormone-naive patients and decreased progressively during ADT. After 10 years of ADT, none of the patients had a normal BMD. The prevalence of osteoporosis, osteopenia, and normal BMD according to the WHO criteria is presented in Figure 1.
Comment
In the present report, we observed a progressive increase in the prevalence of osteoporosis in androgen-suppressed patients with PCa. The prevalence of osteoporosis reached 80% after 10 years of ADT. In addition, the bone mass loss and prevalence of osteoporosis varied according to the BMD site of measurement. Both parameters increased with a longer duration of ADT at all BMD measurement sites. In addition, a high rate of osteoporosis was observed in the hormone-naive patients with PCa.
The
Conclusions
The prevalence of osteoporosis in hormone-naive patients with PCa seems to be high, and it increases progressively with ADT. After 10 years of ADT, more than 80% of patients were at a high risk of osteoporotic fractures. Because the prevalence of osteoporosis increases during ADT, preventive measures are recommended. Additionally, a basal BMD measurement might be useful to identify patients at a greater risk of bone loss who would be candidates for osteoporosis treatment.
References (27)
Osteoporosis after orchiectomy for prostate cancer
J Urol
(1997)- et al.
Skeletal fractures negatively correlate with overall survival in men with prostate cancer
J Urol
(2002) - et al.
Osteoporosis in men
Rheum Dis Clin North Am
(2001) - et al.
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
J Urol
(2003) - et al.
Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma
J Urol
(1999) - et al.
Progressive osteoporosis during androgen deprivation therapy for prostate cancer
J Urol
(2000) - et al.
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy
J Urol
(2002) - et al.
Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression
J Urol
(2006) - et al.
Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment
Eur Urol
(2003) - et al.
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer
Urology
(2001)